Highlights Newsletter 3
This newsletter presents you the following key sessions:
5. Selpercatinib as a first-line standard of care in advanced RET-mutant medullary thyroid cancer
This newsletter presents you the following key sessions:
5. Selpercatinib as a first-line standard of care in advanced RET-mutant medullary thyroid cancer
Medical writer
Medical writer
Medical writer